[EFR-like peptides and their receptors as prognostic factors for the survival of patients with non-small-cell lung cancer].
The levels of EGFR and its ligands have been assayed in tumor and adjacent lung tissues in NSCLC patients. Both EGFR and EGF-like peptides were found in tumor more frequently than in unaltered tissue. It was shown (Kaplan-Meyer) that simultaneous expression of EGFR and its ligands in tumor and adjacent lung tissues was associated with lower overall and relapse-free survival in NSCLC patients.
Kostyleva
O I
OI
N.N. Blokhin Center for Cancer Research, Russian Academy of Medical Sciences, Moscow.
Gerstein
E S
ES
Dykhno
A Iu
AIu
Vasil'ev
A V
AV
Polotskiĭ
B E
BE
Kushlinskiĭ
N E
NE
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D004815:Epidermal Growth Factor / Q000032:analysis*; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry* / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis
D004815:Epidermal Growth Factor; D066246:ErbB Receptors